Mymetics Corp. (MYMX.OB) Monday said the US Patent and Trademark Office has issued a notice of allowance for the patent application "Phospholipid Virosome" # 10/544,939, based on WO 04/071492.
Jacques-François Martin, Chief Executive of Mymetics said, "This patent complements very well the intellectual property portfolio around Mymetics' vaccine pipeline and broadens, in particular, our technology platform to develop other non-influenza virosome based vaccines. It is also an additional confirmation of the importance of our acquisition of Virosome Biologicals last year."
Mymetics already uses this new innovative production method for its Respiratory Syncytial Virus and Herpes Simplex Virus vaccine that are in preclinical development.
The patent, which describes a method for the production of virosome vaccines based on a short-chain phospholipid, was developed by Mymetics BV in collaboration with the University of Groningen, in the Netherlands.
For comments and feedback: editorial@rttnews.com